Suppr超能文献

小檗碱在阿尔茨海默病动物模型中的神经保护作用及可能机制:系统评价与Meta分析

Neuroprotective effects and possible mechanisms of berberine in animal models of Alzheimer's disease: a systematic review and meta-analysis.

作者信息

Dan Lijuan, Hao Yanwei, Li Jiaxin, Wang Tianyuan, Zhao Weiwei, Wang Hui, Qiao Liyan, Xie Peijun

机构信息

School of Clinical Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Department of Geriatrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

出版信息

Front Pharmacol. 2024 Jan 8;14:1287750. doi: 10.3389/fphar.2023.1287750. eCollection 2023.

Abstract

Recently, multiple preclinical studies have reported the beneficial effect of berberine in the treatment of Alzheimer's disease (AD). Nevertheless, the neuroprotective effects and possible mechanisms of berberine against AD are not universally recognized. This study aimed to conduct a systematic review and meta-analysis by integrating relevant animal studies to assess the neuroprotective effects and potential mechanisms of berberine on AD. We systematically searched PubMed, Embase, Scopus and Web of Science databases that reported the effects of berberine on AD models up to 1 February 2023. The escape latency, times of crossing platform, time spent in the target quadrant and pro-oligomerized amyloid beta 42 (Aβ) were included as primary outcomes. The secondary outcomes were the Tau-ps 204, Tau-ps 404, β-site of APP cleaving enzyme (BACE1), amyloid precursor protein (APP), acetylcholine esterase (AChE), tumor necrosis factor ⍺ (TNF-α), interleukin 1β (IL-1β), IL-6, nitric oxide (NO), glial fibrillary acidic protein (GFAP), malonaldehyde (MDA), glutathione S-transferase (GST), glutathione (GSH), glutathione peroxidase (GPx), Beclin-1 and neuronal apoptosis cells. This meta-analysis was conducted using RevMan 5.4 and STATA 15.1. The SYRCLE's risk of bias tool was used to assess the methodological quality. Twenty-two studies and 453 animals were included in the analysis. The overall results showed that berberine significantly shortened the escape latency ( < 0.00001), increased times of crossing platform ( < 0.00001) and time spent in the target quadrant ( < 0.00001), decreased Aβ deposition ( < 0.00001), Tau-ps 202 ( < 0.00001) and Tau-ps 404 ( = 0.002), and improved BACE1, APP, AChE, Beclin-1, neuronal apoptosis cells, oxidative stress and inflammation levels. Berberine may be a promising drug for the treatment of AD based on preclinical evidence (especially when the dose was 5-260 mg/kg). The potential mechanisms for these protective effects may be closely related to anti-neuroinflammation, anti-oxidative stress, modulation of autophagy, inhibition of neuronal apoptosis and protection of cholinergic system. However, these results may be limited by the quality of existing research. Larger and methodologically more rigorous preclinical research are needed to provide more convincing evidence.

摘要

最近,多项临床前研究报告了黄连素在治疗阿尔茨海默病(AD)方面的有益作用。然而,黄连素对AD的神经保护作用及其可能的机制尚未得到普遍认可。本研究旨在通过整合相关动物研究进行系统评价和荟萃分析,以评估黄连素对AD的神经保护作用及其潜在机制。我们系统检索了PubMed、Embase、Scopus和Web of Science数据库,这些数据库截至2023年2月1日报道了黄连素对AD模型的影响。逃避潜伏期、穿越平台次数、在目标象限停留的时间以及前寡聚化淀粉样β-42(Aβ)被作为主要结局指标。次要结局指标包括Tau-ps 204、Tau-ps 404、APP裂解酶β位点(BACE1)、淀粉样前体蛋白(APP)、乙酰胆碱酯酶(AChE)、肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、IL-6、一氧化氮(NO)、胶质纤维酸性蛋白(GFAP)、丙二醛(MDA)、谷胱甘肽S-转移酶(GST)、谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GPx)、Beclin-1和神经元凋亡细胞。本荟萃分析使用RevMan 5.4和STATA 15.1进行。采用SYRCLE偏倚风险工具评估方法学质量。分析纳入了22项研究和453只动物。总体结果表明,黄连素显著缩短了逃避潜伏期(<0.00001),增加了穿越平台次数(<0.00001)和在目标象限停留的时间(<0.00001),减少了Aβ沉积(<0.00001)、Tau-ps 202(<0.00001)和Tau-ps 404(=0.002),并改善了BACE1、APP、AChE、Beclin-1、神经元凋亡细胞、氧化应激和炎症水平。基于临床前证据(特别是当剂量为5-260mg/kg时),黄连素可能是一种有前景的AD治疗药物。这些保护作用的潜在机制可能与抗神经炎症、抗氧化应激、自噬调节、抑制神经元凋亡和保护胆碱能系统密切相关。然而,这些结果可能受到现有研究质量的限制。需要开展更大规模且方法学上更严谨的临床前研究以提供更有说服力的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75fc/10800531/f01bace29935/fphar-14-1287750-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验